GH Research Announces Publication of Phase 2a Postpartum Depression Results
GH Research PLC reported successful Phase 2a trial results for inhaled mebufotenin (GH001) in treating postpartum depression, with 100% remission within two hours sustained through 8 days. The treatment was well-tolerated with minimal side effects and only brief breastfeeding interruption. The company also announced upcoming presentations on Phase …